1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
TaiMed Biologics Inc.

TaiMed Biologics Inc.

TTPEX:4147
61.10
TWD
-1.40
(-2.24%)
-0.51EPS
17.60BMarket Cap
Nov 18Next Earn
TaiMed Biologics Inc.
TPEX:4147
(Taipei Exchange)

Recent

price

61.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
- -
- -
- -
- -
0.01
0.03
0.95
2.76
2.82
1.62
2.2
1.95
2.27
2.24
2.26
Revenue per Share
-1.33
-1.04
-0.86
-1.28
-1.2
-2.13
-1.12
-2.07
-1.26
-2.26
-0.72
-1.84
-1.05
-0.77
-0.75
-0.61
-0.51
Basic EPS, GAAP
-1.05
-0.72
-0.61
-0.85
-0.97
-2.03
-0.72
-3.15
-6.71
-3.1
-2.29
-0.88
-2.38
-0.13
-1.49
0.62
0.39
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.32
5.27
4.5
3.34
8.33
19.53
18.59
16.9
16
14.02
13.35
11.49
10.6
10
14.73
14.12
13.58
Book Value per Share
4.4
3.56
2.79
1.64
6.81
18.2
17.26
15.52
13.48
11.13
9.68
8.28
7.77
7.56
12.76
12.5
12.13
Tangible Book Value per Share
180
196
196
197
235
221
252
254
254
256
256
256
256
253
268
273
274
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
2
8
241
705
722
413
563
492
610
611
619
Sales/Revenue/Turnover
-88,482.76
-178,351.85
- -
- -
- -
- -
-15,072.16
-6,462.97
-133.08
-55.36
-18.38
-117.64
-34.08
-33.8
-41.34
-31.84
-30.27
Operating Margin (%)
68
68
23
23
23
3
3
4
63
93
140
157
156
155
154
154
154
Depreciation Expense
-238
-205
-168
-252
-282
-472
-282
-525
-322
-579
-183
-471
-269
-195
-202
-168
-139
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-74,673.04
-151,496.3
- -
- -
- -
- -
-13,581.98
-6,218.04
-133.47
-82.14
-25.37
-113.91
-47.83
-39.61
-33.08
-27.44
-22.42
Profit Margin (%)
791
650
522
317
1,480
4,549
4,373
3,560
2,283
2,029
2,316
2,110
1,835
1,790
3,259
3,069
2,861
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
32
567
565
550
522
493
463
448
LT Debt
1,041
1,032
884
658
1,830
4,900
4,714
4,292
4,080
3,586
3,416
2,942
2,715
2,566
4,023
3,858
3,676
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-29.06
-19.73
-17.52
-32.65
-22.65
-14.02
-5.87
-11.65
-7.68
-15.09
-5.24
-14.82
-9.52
-7.38
-6.13
-4.26
-3.66
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
30
30
30
LT Borrowings
440
433
426
LT Finance Leases
23
22
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
273
272
271
Market Capitalization
16,720
13,939
17,596

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,322
3,179
3,058
Cash, Cash Equivalents & STI
1,771
1,637
1,607
Accounts Receivable, Net
65
74
32
Inventories
828
810
743
Total Current Liabilities
254
189
198
Payables & Accruals
- -
- -
- -
ST Debt
30
30
30
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.89%
5.12%
-4.11%
Free Cash Flow
134.18%
205.78%
-142.21%
Net Income, GAAP
9.19%
14.63%
-16.87%
Sales/Revenue/Turnover
- -
1%
0.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
179
147
139
146
610
2025
176
138
148
150
611
2026
166
156
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.1
-0.14
-0.45
-0.75
2025
-0.09
-0.22
-0.05
-0.25
-0.61
2026
0.06
-0.27
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
TaiMed Biologics Inc. operates as a specialized biotechnology firm, focusing on the research, development, production, and commercialization of novel pharmaceutical agents for addressing and preventing infectious diseases. The company offers Trogarzo (ibalizumab, TMB-355), a humanized monoclonal antibody, approved in the United States and other regions for individuals living with multidrug-resistant HIV-1 infection, available as both intravenous infusion and IV push formulations. Beyond its marketed product, TaiMed is actively advancing a pipeline of investigational therapies. This includes the long-acting TMB-365 and TMB-380 combination, a dual monoclonal antibody treatment for HIV, which recently completed its Phase 2a clinical study with positive topline results and is poised to enter Phase 2b in 2025, having received U.S. FDA Fast Track designation. The company is also exploring antibody-drug conjugates (ADCs) for potential applications in cancer and precision HIV/autoimmune therapies. Established in 2007 and based in Taipei, Taiwan, TaiMed Biologics additionally provides contract development and manufacturing (CDMO) services for biologics.